Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD) - PubMed (original) (raw)
Clinical Trial
. 2003 Aug 20;42(4):705-8.
doi: 10.1016/s0735-1097(03)00765-4.
Affiliations
- PMID: 12932605
- DOI: 10.1016/s0735-1097(03)00765-4
Free article
Clinical Trial
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)
Michael Domanski et al. J Am Coll Cardiol. 2003.
Free article
Abstract
Objectives: We sought to determine whether non-potassium-sparing diuretics (PSDs) in the absence of a PSD may result in progressive heart failure (HF).
Background: Angiotensin-converting enzyme (ACE) inhibitors incompletely suppress ACE activity in HF patients. Furthermore, non-PSDs are activators of aldosterone secretion. We reasoned that non-PSDs, in the absence of a PSD, might result in progressive HF.
Methods: In the 6,797 patients in the Studies Of Left Ventricular Dysfunction (SOLVD), we compared the risk of hospitalization for, or death from, HF between those taking a PSD and those who were not, adjusting for known covariates.
Results: The risk of hospitalization from worsening HF in those taking a PSD relative to those taking only a non-PSD was 0.74 (95% confidence interval [CI] 0.55 to 0.99; p = 0.047). The relative risk for cardiovascular death was 0.74 (95% CI 0.59 to 0.93; p = 0.011), for death from all causes 0.73 (95% CI 0.59 to 0.90; p = 0.004), and for hospitalization for, or death from, HF 0.75 (95% CI 0.58 to 0.97; p = 0.030). Compared with patients not taking any diuretic, the risk of hospitalization or death due to worsening HF in patients taking non-PSDs alone was significantly increased (risk ratio [RR] = 1.31, 95% CI 1.09 to 1.57; p = 0.0004); this was not observed in patients taking PSDs with or without a non-PSD (RR = 0.99, 95% CI 0.76 to 1.30; p = 0.95).
Conclusions: The use of PSDs in HF patients is associated with a reduced risk of death from, or hospitalization for, progressive HF or all-cause or cardiovascular death, compared with patients taking only a non-PSD.
Comment in
- Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD).
Hernandez AF, O'Connor CM. Hernandez AF, et al. J Am Coll Cardiol. 2003 Aug 20;42(4):709-11. doi: 10.1016/s0735-1097(03)00766-6. J Am Coll Cardiol. 2003. PMID: 12932606 No abstract available. - Diuretic use, progressive heart failure, and death in patients in SOLVD.
Ghali JK. Ghali JK. J Am Coll Cardiol. 2004 May 5;43(9):1723; author reply 1723. doi: 10.1016/j.jacc.2004.02.014. J Am Coll Cardiol. 2004. PMID: 15120837 No abstract available.
Similar articles
- Diuretic use, progressive heart failure, and death in patients in SOLVD.
Ghali JK. Ghali JK. J Am Coll Cardiol. 2004 May 5;43(9):1723; author reply 1723. doi: 10.1016/j.jacc.2004.02.014. J Am Coll Cardiol. 2004. PMID: 15120837 No abstract available. - Diuretic use, progressive heart failure, and death in patients in the DIG study.
Domanski M, Tian X, Haigney M, Pitt B. Domanski M, et al. J Card Fail. 2006 Jun;12(5):327-32. doi: 10.1016/j.cardfail.2006.03.006. J Card Fail. 2006. PMID: 16762792 - ACE inhibitors in heart failure: what more do we need to know?
Demers C, Mody A, Teo KK, McKelvie RS. Demers C, et al. Am J Cardiovasc Drugs. 2005;5(6):351-9. doi: 10.2165/00129784-200505060-00002. Am J Cardiovasc Drugs. 2005. PMID: 16259523 Review. - Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.
Ezekowitz JA, McAlister FA. Ezekowitz JA, et al. Eur Heart J. 2009 Feb;30(4):469-77. doi: 10.1093/eurheartj/ehn543. Epub 2008 Dec 9. Eur Heart J. 2009. PMID: 19066207 Review.
Cited by
- Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients.
Shiraishi Y, Ikemura N, Urashima M, Kohno T, Nakano S, Tanaka T, Nagatomo Y, Ikoma T, Ono T, Numasawa Y, Sakamoto M, Nishikawa K, Takei M, Hakuno D, Nakamaru R, Ueda I, Kohsaka S. Shiraishi Y, et al. BMJ Open. 2024 Feb 14;14(2):e076519. doi: 10.1136/bmjopen-2023-076519. BMJ Open. 2024. PMID: 38355194 Free PMC article. - Ultrafiltration in Heart Failure: A Review.
Bisht H, Tripathi A, Arya A, Konat A, Patel D, Godhani D, Kamaria R, Shah P, Chudasama G, Jain P, Sharma K. Bisht H, et al. Cureus. 2023 Jun 4;15(6):e39933. doi: 10.7759/cureus.39933. eCollection 2023 Jun. Cureus. 2023. PMID: 37409214 Free PMC article. Review. - Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation.
Baudry G, Coutance G, Dorent R, Bauer F, Blanchart K, Boignard A, Chabanne C, Delmas C, D'Ostrevy N, Epailly E, Gariboldi V, Gaudard P, GoƩminne C, Grosjean S, Guihaire J, Guillemain R, Mattei M, Nubret K, Pattier S, Vermes E, Sebbag L, Duarte K, Girerd N. Baudry G, et al. ESC Heart Fail. 2023 Oct;10(5):2843-2852. doi: 10.1002/ehf2.14467. Epub 2023 Jul 5. ESC Heart Fail. 2023. PMID: 37408178 Free PMC article. - How should we treat acute kidney injury caused by renal congestion?
Abe M, Hemmi S, Kobayashi H. Abe M, et al. Kidney Res Clin Pract. 2023 Jul;42(4):415-430. doi: 10.23876/j.krcp.22.224. Epub 2023 Mar 22. Kidney Res Clin Pract. 2023. PMID: 37098670 Free PMC article. - Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.
Takimura H, Kurozumi A, Taniguchi R, Tsuzuki I, Tajima E, Yamaguchi Y, Kawano M, Takimura Y, Nishio S, Nakano M, Tsukahara R. Takimura H, et al. Am J Cardiovasc Drugs. 2023 Mar;23(2):185-196. doi: 10.1007/s40256-023-00571-y. Epub 2023 Feb 4. Am J Cardiovasc Drugs. 2023. PMID: 36739357
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous